View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Dan Salmon
  • Dan Salmon

The Trade Desk (TTD, Neutral, $75 target) Continued revenue decelerati...

In this first take following tonight’s results, we touch on: 1. 3Q25 revenue deceleration hangs over the stock 2. Management remains confident that Amazon DSP is not a competitor 3. Kokai adoption reaches three quarters of spend 4. CFO transition announced, other leadership changes evolve go-to-market

Dan Salmon
  • Dan Salmon

Amazon (AMZN, Buy, $270 target) AWS adds OpenAI open weight models (an...

Earlier today, OpenAI released its promised open weight models and they are available on a variety of platforms, including AWS and Azure but not GCP. This is the first time any OpenAI models have been available through AWS.

Amazon Com Inc: 1 director

A director at Amazon Com Inc sold 2,500 shares at 217.000USD and the significance rating of the trade was 58/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...

Dan Salmon
  • Dan Salmon

Amazon (AMZN, Buy, raising target to $270) How OpenAI could unleash th...

AMZN remains our Top Pick, based on 2H25/1H26 AWS revenue acceleration, albeit lagging GCP and Azure. That AWS appears to be more capacity constrained than Azure and GCP is not a big surprise. MSFT has the largest base of GPUs, while GOOGL has a larger custom silicon base. We expect AWS to accelerate as it closes the gap on custom silicon, ramping into Trainium3 later this year.

Vikash Harlalka
  • Vikash Harlalka

Autumn for Broadband 2Q25

In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Net adds remained nearly flat compared to a year ago (when adjusted for ACP impact) but were within the pre-pandemic norm. Industry subscriber trends have mostly stabilized over the past 3 quarters, but y/y growth remains below pre-pandemic levels.

Wedbush Research
  • Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
HURN HURON CONSULTING GROUP INC.
GME GAMESTOP CORP. CLASS A
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BZH BEAZER HOMES USA INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
INOD INNODATA
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
CVCO CAVCO INDUSTRIES INC.
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ROKU ROKU INC. CLASS A
ISR ISORAY
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
UBER UBER TECHNOLOGIES INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
U UNITY SOFTWARE
TVTX TRAVERE THERAPEUTICS INC
PLTR PALANTIR TECHNOLOGIES
VRDN VIRIDIAN THERAPEUTICS INC
IMNM IMMUNOME
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
DAWN DAY ONE BIOPHARMACEUTICALS INC
STX SEAGATE TECHNOLOGY HLDGS PLC
ATXS ASTRIA THERAPEUTICS INC
GFS GLOBALFOUNDRIES INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
DDI DOUBLEDOWN INTERACTIVE CO LTD
APGE APOGEE THERAPEUTICS INC
SKLZ SKILLZ INC
EMBRAC B EMBRACER GROUP AB
DNTH DIANTHUS THERAPEUTICS INC
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
Daniel Ives ... (+3)
  • Daniel Ives
  • Matthew Weiss
  • Scott Devitt

Expectations Investing; OP, $250 PT

Figure 1. 2Q25 ResultsSource: Company reports, Wedbush estimates, FactSet consensusGuidance notes: 2Q total revenue guidance of $159B to $164B; 2Q operating income guidance of $13.0B to $17.5B.In 2Q, total revenues grew +13.3% Y/Y, ~3% ahead of expectations, driven by outperformance across all segm

Dan Salmon
  • Dan Salmon

Amazon (AMZN, Buy, $260 target) AWS’s day is coming, but today is not ...

In this first take following tonight’s results, we focus on: 1. AWS revenue growth beats consensus but the real question is 2H acceleration 2. Increased 2025 capex guidance no surprise but no early hints for 2026 3. Custom silicon, price, and incumbent workloads define the long-term AWS AI strategy 4. Tariff uncertainty weighs on retail outlook, but underlying fundamentals remain strong

 PRESS RELEASE

XPO Reports Second Quarter 2025 Results

XPO Reports Second Quarter 2025 Results GREENWICH, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- (NYSE: XPO) today announced its financial results for the second quarter 2025. The company reported diluted earnings per share of $0.89, compared with $1.25 for the same period in 2024, and adjusted diluted earnings per share of $1.05, compared with $1.12 for the same period in 2024. Second Quarter 2025 Summary Results                   Three Months Ended June 30,    Revenue Operating Income (Loss)(in millions)  2025  2024 Change %  2025  2024 Change %North American Less-Than-Truckload Segment $  ...

Daniel Ives ... (+3)
  • Daniel Ives
  • Matthew Weiss
  • Scott Devitt
Jonathan Chaplin
  • Jonathan Chaplin

AT&T Model Update

We have updated the model following results. Changes to the segments are not material, but changes to capex, cash taxes and free cash flow in light of the OBBBA are. For thoughts following the call, click here. For a review of results, click here. (Rating: Buy; TP: $32; Total Return: +20%).

Jonathan Chaplin
  • Jonathan Chaplin

AT&T quick thoughts following the call 2Q25

In this note we cover evolving thoughts on the implications of the new Cable MVNO, the implications of AT&T’s revised capital allocation decisions, new insights on the pace of fiber deployment, a shift in the FWA strategy, the implications of both for cable, comments on spectrum purchases, the implications for EchoStar, and an early take on mobile and broadband market growth.

Jonathan Chaplin
  • Jonathan Chaplin

AT&T 2Q25 Quick Take: Results strong; FCF guide increased, but less th...

Postpaid phone adds beat estimates, which will come as a relief following Verizon’s results. Service revenue, EBITDA, EPS, and FCF were all slightly better than expected. The Company increased FCF guidance following OBBBA, but by less than some had hoped. In addition, the Company did not commit to increasing share repurchases with the increased FCF.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch